Gliomas are molecularly heterogeneous brain tumors responsible for the most years of life
lost by any cancer. High-grade gliomas have a poor prognosis and despite multimodal …

Alterations of the v-raf murine sarcoma viral oncogene homolog B (BRAF) have been
extensively studied in several tumor entities and are known to drive cell growth in several …

Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …

Kinase inhibitors are effective cancer therapies, but tumors frequently develop resistance.
Current strategies to circumvent resistance target the same or parallel pathways. We report …

Diffuse gliomas with K27M histone mutations (H3K27M glioma) are generally characterized
by a fatal prognosis, particularly affecting the pediatric population. Based on the molecular …

Abstract BRAF V600E mutations occur frequently in malignant melanoma, but are rare in
most malignant glioma subtypes. Besides, more benign brain tumors such as ganglioglioma …

BRAFV600E mutations have been identified in a number of glioma subtypes, most
frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and …

Outcomes for children with high-grade gliomas (HGG) remain dismal despite aggressive
treatment strategies. The use of targeted therapy for BRAF V600E mutated malignancies …

BRAF V600 mutations are being identified in patients with primary brain tumors more often
as molecular testing becomes widely available. Targeted treatment with BRAF inhibitors has …

BRAF (alternately referred to as v-raf murine sarcoma viral oncogene homolog B1) is a proto-
oncogene involved in the mitogen-activated protein kinase (MAPK) pathway. BRAF …